| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 163.18 | 5.1% |
| Total Income | 163.53 | 5.9% |
| Expenditure | 149.93 | 3.1% |
| PBT | 13.61 | 28.6% |
| Net Profit | 13.49 | 33.4% |
| OPM | 14.98% | 2.24pp |
| NPM | 8.25% | 3.40pp |
| EPS | 4.12 | 33.3% |
Wanbury Ltd Q1FY26 PAT Surges to ₹13.5 Crore vs ₹1.0 Crore YoY
06 Aug 2025 · 6 Aug 2025, 08:49 am
Summary
Wanbury Ltd, a pharmaceutical company, has announced its Q1FY26 financial results. The company reported a significant surge in Profit After Tax (PAT) and EBITDA, driven by higher sales volumes in key API products and strong sales performance in the Branded Formulations segment. The company also launched an innovative liposomal iron supplement and received GMP certification from Brazil’s health authority ANVISA for its API manufacturing sites.
Key Highlights
- 1
Revenue from Operations for Q1FY26 stood at ₹163.2 crore, up from ₹131.1 crore in Q1FY25, reflecting a strong YoY growth of 24%.
- 2
EBITDA (including other income) for the quarter stood at ₹24.8 crore, compared to ₹11.9 crore in Q1FY25, registering a growth of 108%.
- 3
PAT for the quarter stood at ₹13.5 crore, compared to ₹1.0 crore in Q1FY25, registering a growth of 1198%.
- 4
Wanbury Limited has successfully launched its innovative liposomal iron supplement, Vanbury C RED, in the Indian market.
- 5
Wanbury Limited’s API manufacturing sites at Patalganga and Tanuku have both successfully received Good Manufacturing Practices (GMP) certification from Brazil’s health authority ANVISA.
Management Comments
Mr. Mohan Rayana
Director of Wanbury Ltd.
Q1 FY26 marks a strong recovery for Wanbury, with both manufacturing facilities operating at healthy capacity levels post last year’s planned upgradation. This has positively impacted our top line and profitability, setting a strong tone for the year ahead.
Informational and educational content only. Not investment advice.